- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Migraine
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 851KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 163KB)
Galcanezumab – March 2022
Galcanezumab: Injection 120 mg in 1 mL pre-filled pen; Emgality®
Last updated
1 July 2022